Thoughts on GSK’s Decision to Terminate its Collaboration with Immatics
Here is a brief preview of this blast: On Thursday, November 17, Immatics held its Q3 2022 earnings call (press release / presentation) disclosing GSK's decision to terminate their collaboration to develop novel adoptive cell therapies. Below, Celltelligence provides insights on how GSK’s decision to deprioritize its cell therapy programs could affect Immatics's strategy, while discussing how BMS could benefit from it.